Aardvark Therapeutics' stock dropped 32% following the FDA's decision to place a full clinical hold on its lead drug candidate ARD-101, used to treat Prader-Willi Syndrome. This follows a prior 56% drop in March when the company paused its Phase 3 trial due to serious safety concerns involving cardiac issues. The clinical hold affects all ongoing studies under the drug's IND application, raising questions about the drug's safety and efficacy claims. A shareholder rights firm is investigating whether Aardvark misled investors about these issues, and investors with losses are encouraged to come forward.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
